Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

Running, not enrolling

Conditions studied: Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration

In brief

This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study

Key facts

Study ID

NCT06162585

Run by

Nanoscope Therapeutics Inc.

People needed

18

Starts

2023-12-08

Expected to finish

2027-09-01

Last updated by the study team

2025-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously enrolled in study NTXMCO-002 (RESTORE)
• Able to comprehend and give informed consent.
• Able to comply with testing and all protocol tests.
• Agree to participate for the full 3-year duration of follow-up to the best of their ability and barring any unforeseen circumstances.

You may not qualify if…

• Not applicable. Subjects will be included in this study and will be consented after completion of all assessments at their final RESTORE study visit

Where it is running

• Nanoscope Clinical Site — Beverly Hills, California, United States
• Nanoscope Clinical Site — Pensacola, Florida, United States
• Nanoscope Clinical Site — Fargo, North Dakota, United States
• Nanoscope Clinical Site — Houston, Texas, United States
• Nanoscope Clinical Site — McAllen, Texas, United States
• Nanoscope Clinical Site — Arecibo, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.